100–500 mg orally. The evidence as a supplement is weak; part of the effect may be placebo or via the gut-brain axis (vagus nerve). Not to be confused with the endogenous molecule.
As an endogenous molecule, GABA is the target of most anxiolytics and sedatives (benzodiazepines, alcohol, kava, Silexan, apigenin). Low GABA tone is associated with anxiety and insomnia.
View the study (review) →Some signal of relaxation, with weak evidence. The effect is probably partial, via the gut-brain axis rather than directly central.
View the study (clinical trial) →May shorten the time to fall asleep somewhat; limited data.
View the study (systematic review) →GABAergic modulation is the mechanism shared by the anxiolytics with the best evidence in GAD. As an oral supplement, it is unclear how much it contributes to this effect.
⏱ 2 min read
Gamma-aminobutyric acid, or GABA, is the main inhibitory neurotransmitter of the mammalian central nervous system: it acts by slowing neuronal excitability through specific receptors (ionotropic GABA-A and metabotropic GABA-B) whose pharmacological modulation is the basis of action of some of the most widely used therapeutic groups in modern medicine, including benzodiazepines, barbiturates, gabapentinoids, baclofen, and some anticonvulsants; the commercial promise of GABA supplements is to replicate part of these pharmacological effects by consuming the neurotransmitter itself orally, a questionable premise for pharmacokinetic reasons that deserve careful analysis.
The fundamental problem with GABA as an oral supplement is that its molecule does not efficiently cross the blood-brain barrier in adult humans: GABA is a small polar molecule with no specific transporter identified at the barrier and, in rigorous pharmacokinetic studies, it reaches minimal brain concentrations after oral administration; the clinical effects observed in some studies (anxiolysis, improved sleep, reduced blood pressure) could be explained by peripheral mechanisms (enteric nervous system, sympathetic system) or by a significant placebo effect rather than by a direct central action.
Several small studies have shown subjective improvements on acute anxiety scales and changes in the electroencephalographic tracing (increased alpha waves, a marker of relaxation) with single doses of 100-200 milligrams of oral GABA, especially in specific formulations such as GABA produced by bacterial fermentation with Lactobacillus hilgardii (PharmaGABA); the effect is modest and heterogeneous, and its magnitude is not comparable to that of pharmacological anxiolytics.
For sleep, doses of 100-300 milligrams of GABA taken 30-60 minutes before bedtime have shown subjective improvements in sleep latency and quality in small studies, comparable to other nutritional interventions with an anxiolytic profile (L-theanine, glycine, magnesium); the polysomnographic effects are less consistent and the clinical magnitude is modest, enough as an aid in mild functional insomnia but clearly insufficient for severe insomnia.
Some small Japanese trials have documented modest reductions in systolic and diastolic blood pressure (3-8 mmHg) with chronic supplementation of 80-100 milligrams per day over weeks to months; these effects could be explained by peripheral mechanisms on the sympathetic system and are consistent with the available data on GABA as an autonomic modulator.
The doses studied range from 100 to 750 milligrams per day, divided into one or several doses depending on the indication; for anxiety or sleep, 100-300 mg acutely before the critical moment; for autonomic modulation, 80-100 mg daily on a sustained basis; products made by natural fermentation (PharmaGABA) have better clinical documentation than those obtained by chemical synthesis, although there are no convincing direct comparisons; the subjective effect is usually acute, within the hour after the dose.
Generally well tolerated; the adverse effects described are rare and mild (drowsiness, tingling, occasionally headache or nausea at high doses); people taking pharmacological anxiolytics (benzodiazepines, gabapentinoids, sedating antihistamines) should be cautious because of possible mild potentiation, although the limited brain bioavailability of oral GABA reduces the risk of significant drug interactions; in pregnancy and breastfeeding the data are limited and avoiding use as a precaution is recommended; oral GABA is not an alternative to benzodiazepines in anxiety disorders or insomnia that require medical treatment, but rather a nutritional intervention with modest expectations and an unclear central mechanism.
Information, not medical advice. Scientific evidence reflects the quality of the studies.